Prof Neoptolemos meets with ecancertv at ASCO 2016 to discuss ESPAC-4, an international phase III trial of gemcitabine and capecitabine in combination, or as mono therapy, for patients with resected pancreatic ductal adenocarcinoma.
With 732 patients, the European Study Group for Pancreatic Cancer (ESPAC) 4 trial is the second-largest clinical trial ever conducted in patients with pancreatic cancer who had undergone surgery.
The median overall survival was 28.0 months with the combination regimen vs. 25.5 months with gemcitabine alone, and the estimated 5-year survival rates were 28.8% vs. 16.3% in the two groups.
ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.